Esketamine nasal spray for treatment‐resistant depression
Prescriber May 1, 2020 DOI: 10.1002/psb.1845
Summary
AI-generated from the abstractA nasal spray formulation of esketamine (Spravato) was licensed in December as an add-on treatment for adults with treatment-resistant major depression. The article reviews the drug's properties, evidence from clinical trials on its effectiveness, and its side effects.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Population | Adults with treatment-resistant major depression |
| Citations | 1 |
| Key finding | Esketamine nasal spray (Spravato) is a new adjunctive therapy for treatment-resistant major depression, with its efficacy and adverse effects discussed based on clinical trial data. |
Abstract
A nasal spray formulation of esketamine (Spravato) was licensed as adjunctive therapy for the management of adults with treatment‐resistant major depression in December. This article discusses the properties, clinical trial efficacy and adverse effects of this new treatment option.